Results 161 to 170 of about 44,405 (256)

Biomarkers in patients with clinical signs of mild cognitive impairment or mild Alzheimer's disease but without amyloid deposits on positron emission tomography: Results from Bio‐Hermes Study participants

Alzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) study participants may present with cognitive impairment who do not have brain amyloid deposits (Aβ−). Identifying predictive biomarkers for non‐amyloid‐related CI may provide better screening tests for trials seeking only CI Aβ+ participants and new therapy targets.
Richard C. Mohs, Douglas W. Beauregard, Lynne Hughes, Cyndy B. Cordell, Allan I. Levey, Saima Rathore, Nicholas T. Seyfried, Erik C. B. Johnson, Jessie Nicodemus‐Johnson, Joshua Christensen, Robin Wolz, John Dwyer   +11 more
wiley   +1 more source

Efficacy and Safety of IncobotulinumtoxinA for Treatment of Sialorrhea: A Multicenter, Phase 3 Study in Japan

Movement Disorders Clinical Practice, Volume 13, Issue 1, Page 120-130, January 2026.
This study demonstrated significant treatment efficacy and safety of incobotulinumtoxinA injection in Japanese patients with chronic sialorrhea caused by Parkinson's disease and other neurological conditions. Suppression of salivary secretion and improvement in drooling symptoms were also observed throughout 48 weeks.
Nobutaka Hattori, Yohei Mukai, Noriko Nishikawa, Kazuko Hasegawa, Masahiko Tomiyama, Yasuyoshi Kimura, Yoshio Tsuboi, Ryosuke Takahashi, Ryota Nakamura, Yuishin Izumi, Hirohisa Watanabe, Morinobu Seki, Kenji Sekiguchi, Shohei Tateishi, Yusaku Matsushita, Yusaku Nakamura   +15 more
wiley   +1 more source

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria

Movement Disorders, 2017
Günter U. Höglinger, G. Respondek, M. Stamelou, C. Kurz, K. Josephs, A. Lang, B. Mollenhauer, U. Müller, C. Nilsson, J. Whitwell, T. Arzberger, E. Englund, E. Gelpí, A. Giese, D. Irwin, W. Meissner, Alexander Y. Pantelyat, A. Rajput, J. V. van Swieten, C. Troakes, A. Antonini, K. Bhatia, Y. Bordelon, Y. Compta, J. Corvol, C. Colosimo, D. Dickson, R. Dodel, L. Ferguson, M. Grossman, J. Kassubek, F. Krismer, J. Levin, S. Lorenzl, H. Morris, P. Nestor, W. Oertel, W. Poewe, G. Rabinovici, J. Rowe, G. Schellenberg, K. Seppi, Thilo van Eimeren, G. Wenning, A. Boxer, L. Golbe, I. Litvan   +46 more
semanticscholar   +1 more source

Mapping Alzheimer's disease heterogeneity with molecular imaging biomarkers

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
This review outlines positron emission tomography (PET) biomarkers used in Alzheimer's disease (AD) research and clinical settings, targeting both specific (amyloid, tau) and non‐specific (neurodegeneration, synaptic density, neuroinflammation) processes.
Elif Harput, Cecilia Boccalini, Gregory Mathoux, John O. Prior, Nathalie Testart, Mario Jreige, Valentina Garibotto   +6 more
wiley   +1 more source

Extracellular Vesicle‐Derived microRNAs as Fluid Biomarkers in Neurodegenerative Diseases: A Systematic Review

Journal of Neurochemistry, Volume 170, Issue 1, January 2026.
Given the absence of curative treatments for neurodegenerative diseases, early detection and therapeutic intervention are critical to slowing disease progression. The last decade has seen accumulating evidence for microRNA dysregulation in circulating extracellular vesicles (EVs); however, assessing reproducibility between studies remains challenging ...
Aliyah Zaman, Sienna S. Drake, Alyson E. Fournier   +2 more
wiley   +1 more source

“Rapidly” Progressive Supranuclear Palsy [PDF]

Movement Disorders Clinical Practice, 2014
Melissa J, Armstrong, Rudy J, Castellani, Stephen G, Reich   +2 more
openaire   +2 more sources

Reply to “Neurophysiological Testing to Diagnose Stiff‐Person Spectrum Disorder”

Movement Disorders Clinical Practice, Volume 13, Issue 1, Page 303-304, January 2026.
João Moura, Lorenzo Rocchi, Michael Zandi, Bettina Balint, Kailash P. Bhatia, Anna Latorre   +5 more
wiley   +1 more source

Hummingbird sign in progressive supranuclear palsy disease

Journal of Research in Medical Sciences, 2012
Progressive supranuclear palsy (PSP) is characterized by slowness, rigidity, bradykinesia, repeated falls, downgaze limitation and dementia. Midbrain atrophy on magnetic resonance imaging is highly suggestive of PSP and is described as "hummingbird sign".
Sanjay Pandey
doaj  

A case of atypical progressive supranuclear palsy

Clinical Interventions in Aging, 2013
Simona Spaccavento, Marina Del Prete, Angela Craca, Anna Loverre IRCCS Salvatore Maugeri Foundation, Cassano Murge, Bari, Italy Background: Progressive supranuclear palsy (PSP) is a neurodegenerative extrapyramidal syndrome.
Spaccavento S, Del Prete M, Craca A, Loverre A   +3 more
doaj  

Richardson Syndrome Variant of Progressive Supranuclear Palsy: A Case Report. [PDF]

Cureus
Korucu I, Karakoyun Alpay T.
europepmc   +1 more source